Royalty Pharma plc Class A Ordinary Shares(RPRX)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

RPRX $57.30
Snapshot
$57.30
52-Week Range
$34.08 – $59.44
YTD
+47.44%
IV Rank (30D)
23.36
Straddle Price
$4.17
P/C Vol Ratio
2.97
Market Cap
$25.8B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.57%
Beta vs SPY1.00
Cost of Equity (CAPM)10.07% (VRP-adj)
WACC8.87%
Volatility Risk Premium+21.3pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+9.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.09 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$2.6B
Return on Equity (TTM)12.0%
Book / Price30.9% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)107.0%
Debt / Equity0.86
Quality Score3/6 — normal (10y DCF)
Market-Implied Growth+1.7% (reverse-DCF on current price)
SMA 50$54.87 (Market Anchor value)
SMA 20 / Bollinger Mid$56.53
Bollinger Width / SMA2017.0% (drives anchor stability)
Net Debt$8.0B
Market Cap$32B
Peers used for multiples: AMGN, BIIB, GILD, JNJ, LLY, MRK, REGN, VRTX
Model Conviction
25%
20-Day Fair Value
≈ by Aug 19, 2026
$60.30
α +5.2% rank 50%
40-Day Fair Value
≈ by Sep 17, 2026
$61.91
α +8.0% rank 42%
60-Day Fair Value
≈ by Oct 16, 2026
$58.94
α +2.9% rank 53%
MethodImplied PriceWeightDetail
DCF $95.68 29%
DDM (Gordon) $23.71 0%
Peer P/E $55.94 9% median 26.9× · 8 peers
Peer EV/EBITDA $36.77 9% median 17.8× · 8 peers
Peer P/B $123.59 9% median 7.0× · 8 peers
Peer P/S $25.89 9% median 5.5× · 8 peers
Market Anchor (SMA50) $54.87 37% stability 65% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-07-21 · updated
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$25.8B

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Summary
composite
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -3.58% 18
Feb +2.14% 17
Mar -0.17% 17
Apr +12.68% 17
May -0.03% 18
Jun -3.58% 19
Jul -2.95% 19
Aug +2.64% 18
Sep -5.07% 18
Oct -4.61% 18
Nov +3.83% 18
Dec +14.06% 18
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $56.53
SMA 50: $54.87
SMA 200: $45.41
Current: $57.30
EMA 12: $57.04
EMA 26: $56.20
MACD: 0.8434 | Signal: -0.0247
BULLISH
ADX (14): 24.10
WEAK TREND
+DI: 29.43
−DI: 21.39
Momentum Oscillators
RSI (14): 55.22
NEUTRAL
Stoch %K: 72.28
Stoch %D: 68.60
Williams %R: -47.77
Volume & Volatility
BB Upper: $59.24
BB Lower: $53.82
NEUTRAL
OBV: 383,473,885
Vol SMA 20: 3,200,838
Vol ROC: 4.49%
ATR: $1.43
True Range: $1.73
HV 20: 31.5%
HV 30: 28.9%
HV 60: 24.4%

Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-07-22T00:00:00 – 2026-07-20T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
8 of 8 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-08 After-Close 8.08% 1.00% 0.12x Within
2024-11-06 After-Close 5.46% 1.52% 0.28x Within
2025-01-10 After-Close 4.07% 1.70% 0.42x Within
2025-05-08 Pre-Market 8.80% 1.03% 0.12x Within
2025-08-06 After-Close 4.67% 3.95% 0.85x Within
2025-11-05 After-Close 9.15% 0.89% 0.10x Within
2026-02-11 After-Close 3.73% 1.04% 0.28x Within
2026-05-06 Pre-Market 5.00% 0.53% 0.11x Within
Options Activity
IV Rank (30D)
23.36
IV Rank (7D)
23.36
Avg IV
50.2%
Straddle (30D)
$4.17
Straddle (7D)
$4.17
P/C Volume
2.97
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
pts EXTREME
ATM — / Wing —
30 DTE / 10d
pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.24
Correlation (SPY)
13.4%
0.02
Ann. Volatility
22.9%
SPY Volatility
12.6%

Low volatility - stock moves less than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 560,800,250 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

594 filers364,382,331 shares$16.45B value64.98% of float
# Filer Shares Value % of Total % of Float Period
1 MORGAN STANLEY Custodian 55,274,069 $2.14B 12.98% 9.86% 2025-12-31
2 Capital International Investors 35,005,736 $1.68B 10.21% 6.24% 2026-03-31
3 BlackRock, Inc. Custodian 25,907,745 $1.24B 7.55% 4.62% 2026-03-31
4 FMR LLC Custodian 25,152,242 $1.21B 7.33% 4.49% 2026-03-31
5 BAILLIE GIFFORD & CO 16,155,677 $774.99M 4.71% 2.88% 2026-03-31
6 Swedbank AB 10,726,608 $601.44M 3.66% 1.91% 2026-06-30
7 STATE STREET CORP 10,989,851 $527.18M 3.20% 1.96% 2026-03-31
8 Capital World Investors 8,036,714 $385.52M 2.34% 1.43% 2026-03-31
9 VANGUARD GROUP INC Custodian 9,934,612 $383.87M 2.33% 1.77% 2025-12-31
10 GEODE CAPITAL MANAGEMENT, LLC Custodian 7,869,632 $376.52M 2.29% 1.40% 2026-03-31
11 ADAGE CAPITAL PARTNERS GP, L.L.C. 7,480,633 $358.85M 2.18% 1.33% 2026-03-31
12 Caledonia (Private) Investments Pty Ltd 7,168,399 $343.87M 2.09% 1.28% 2026-03-31
13 VICTORY CAPITAL MANAGEMENT INC 3,853,808 $184.87M 1.12% 0.69% 2026-03-31
14 NORTHERN TRUST CORP Custodian 3,808,735 $182.71M 1.11% 0.68% 2026-03-31
15 ROYAL LONDON ASSET MANAGEMENT LTD 3,808,353 $182.69M 1.11% 0.68% 2026-03-31
16 AQR CAPITAL MANAGEMENT LLC Custodian 3,782,038 $179.65M 1.09% 0.67% 2026-03-31
17 Patient Capital Management, LLC 3,643,716 $174.79M 1.06% 0.65% 2026-03-31
18 BANK OF AMERICA CORP /DE/ Custodian 3,495,846 $167.70M 1.02% 0.62% 2026-03-31
19 Legal & General Group Plc Custodian 3,362,872 $161.32M 0.98% 0.60% 2026-03-31
20 UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME Custodian 3,095,766 $148.50M 0.90% 0.55% 2026-03-31
21 Amundi Custodian 3,088,773 $148.17M 0.90% 0.55% 2026-03-31
22 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 3,027,899 $145.25M 0.88% 0.54% 2026-03-31
23 CITADEL ADVISORS LLC Custodian 2,681,069 $128.61M 0.78% 0.48% 2026-03-31
24 NEW SOUTH CAPITAL MANAGEMENT INC 2,625,863 $125.96M 0.77% 0.47% 2026-03-31
25 Regal Partners Ltd 2,624,472 $125.90M 0.77% 0.47% 2026-03-31
10 filers$42.85M notional
# Filer Notional Value % of Total Period
1 CITADEL ADVISORS LLC Custodian $10.42M 24.33% 2026-03-31
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $10.16M 23.71% 2026-03-31
3 JANE STREET GROUP, LLC Custodian $9.33M 21.76% 2026-03-31
4 GROUP ONE TRADING LLC Custodian $4.22M 9.84% 2026-03-31
5 SIMPLEX TRADING, LLC Custodian $3.67M 8.58% 2026-03-31
6 TUDOR INVESTMENT CORP ET AL $2.17M 5.06% 2026-03-31
7 Twin Tree Management, LP $1.28M 2.99% 2026-03-31
8 GOLDMAN SACHS GROUP INC Custodian $1.20M 2.80% 2026-03-31
9 JPMORGAN CHASE & CO Custodian $324.59K 0.76% 2026-03-31
10 HAP TRADING, LLC $76.94K 0.18% 2025-09-30
5 filers$14.85M notional
# Filer Notional Value % of Total Period
1 JANE STREET GROUP, LLC Custodian $8.52M 57.40% 2026-03-31
2 SIMPLEX TRADING, LLC Custodian $2.00M 13.44% 2026-03-31
3 CITADEL ADVISORS LLC Custodian $1.97M 13.28% 2026-03-31
4 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $1.25M 8.43% 2026-03-31
5 GROUP ONE TRADING LLC Custodian $1.11M 7.46% 2026-03-31
Insider Activity
Latest: 2026-07-02
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-07-02 Christopher Hite EVP & Chairman, Partnering Sell (S) −130,000 $56.50 -$7.35M EDGAR
2026-07-02 Marshall Urist EVP, Research & Investments Sell (S) −9,099 $55.88 -$508.5K EDGAR
2026-06-25 Marshall Urist EVP, Research & Investments Sell (S) −9,098 $55.18 -$502.1K EDGAR
2026-06-25 Christopher Hite EVP & Chairman, Partnering Sell (S) −150,000 $54.40 -$8.16M EDGAR
2026-06-08 Bonnie L Bassler Director Award (A) +4,545 EDGAR
2026-06-08 DAVID C HODGSON Director Award (A) +4,545 EDGAR
2026-06-08 Gregory Norden Director Award (A) +4,545 EDGAR
2026-06-08 Carole Ho Director Award (A) +4,545 EDGAR
2026-06-08 Catherine M. Engelbert Director Award (A) +4,545 EDGAR
2026-06-08 TED W LOVE Director Award (A) +4,545 EDGAR
2026-06-08 Vlad Coric Director Award (A) +4,545 EDGAR
2026-06-08 ELIZABETH H WEATHERMAN Director Award (A) +4,545 EDGAR
2026-05-28 Terrance P. Coyne EVP & CFO Sell (S) −64,399 $53.98 -$3.48M EDGAR
2026-05-21 Marshall Urist EVP, Research & Investments Sell (S) −13,684 $52.75 -$721.8K EDGAR
2026-05-15 Gregory Norden Director Sell (S) −3,045 $53.00 -$161.4K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
27 insiders · @ $57.30
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Adage Capital Partners, L.P. 10%+ Owner 46,015,330 $2.64B $420.00M 1 2020-06-22
2 Adage Capital Advisors, L.L.C. 10%+ Owner 38,714,280 $2.22B -$1.60B 1 2020-12-18
3 GG 1978 SICAF SIF S.A. 10%+ Owner 22,924,176 $1.31B -$175.5K 1 2022-08-29
4 MGG Strategic SICAF SIF S.A. - MGG Strategic 10%+ Owner 22,657,815 $1.30B -$48.31M 1 2022-09-20
5 Avara Management Ltd 10%+ Owner 22,232,747 $1.27B -$205.44M 6 2024-01-03
6 GG 1978 SICAF SIF S.A. - GG Strategic 10%+ Owner 21,426,170 $1.23B -$118.95M 5 2022-09-22
7 Mario Germano Giuliani Director 7,802,819 $447.06M -$53.65M 4 2023-12-29
8 Skyeline Management Ltd 10%+ Owner 7,795,072 $446.62M -$10.91M 1 2022-12-07
9 WILLIAM E FORD Director 1,506,597 $86.32M $42.00M 4 2021-06-30
10 Pablo G. Legorreta CEO, Chairman of the Board 1,249,534 $71.59M $19.59M 17 2026-05-08
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-07-01
Last 30d: 5 filings · $16.5M notice value  ·  Last 90d: 10 filings · $23.3M notice value · 5 unique filers · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Parsed directly from EDGAR primary-doc XML. Daily refresh; new filings typically appear here the morning after they hit EDGAR.

Top 90-day filers: SCH Investment Partners LLC (2, $13.9M) · Terrance Coyne (2, $5.2M) · Urist Marshall (4, $2.5M) · Christopher Hite (1, $1.7M) · Norden Gregory (1, $161K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-07-01 Urist Marshall Officer 9,099 $508.5K 2026-07-01 Merrill Lynch 10b5-1 EDGAR
2026-07-01 SCH Investment Partners LLC Officer 100,000 $5.71M 2026-06-30 Merrill Lynch 10b5-1 EDGAR
2026-06-24 Urist Marshall Officer 9,098 $502.1K 2026-06-24 Merrill Lynch 10b5-1 EDGAR
2026-06-23 Christopher Hite Officer 30,000 $1.66M 2026-06-23 Merrill Lynch 10b5-1 EDGAR
2026-06-23 SCH Investment Partners LLC Officer 150,000 $8.17M 2026-06-23 Merrill Lynch 10b5-1 EDGAR
2026-05-26 Terrance Coyne Officer 64,399 $3.47M 2026-05-26 Goldman Sachs & Co. LLC 10b5-1 EDGAR
2026-05-20 Urist Marshall Officer 13,684 $721.8K 2026-05-20 Merrill Lynch 10b5-1 EDGAR
2026-05-14 Norden Gregory Officer 3,045 $161.4K 2026-05-14 Merrill Lynch 10b5-1 EDGAR
2026-05-14 Urist Marshall Officer 13,684 $726.1K 2026-05-14 Merrill Lynch 10b5-1 EDGAR
2026-04-28 Terrance Coyne Officer 34,791 $1.72M 2026-04-28 Goldman Sachs & Co. LLC 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
Recent SEC Filings
Latest: 2026-06-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-06-04 0001193125-26-257432 EDGAR
2026-05-28 0001193125-26-245163 EDGAR
2026-05-06 0001802768-26-000008 EDGAR
2026-04-13 0001193125-26-152145 EDGAR
2026-02-11 0001802768-26-000002 EDGAR
2025-12-22 0001193125-25-328100 EDGAR
2025-12-22 0001193125-25-328759 EDGAR
2025-11-05 0001802768-25-000113 EDGAR
2025-09-16 0001193125-25-204983 EDGAR
2025-08-13 0001193125-25-179892 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-11 0001802768-26-000003 EDGAR
2025-02-12 0001802768-25-000010 EDGAR
2024-02-15 0001802768-24-000012 EDGAR
2023-02-15 0001802768-23-000007 EDGAR
2022-02-15 0001802768-22-000011 EDGAR
2021-02-24 0001802768-21-000006 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-05-06 0001802768-26-000009 EDGAR
2025-11-05 0001802768-25-000114 EDGAR
2025-08-06 0001802768-25-000095 EDGAR
2025-05-08 0001802768-25-000027 EDGAR
2024-11-06 0001802768-24-000058 EDGAR
2024-08-08 0001802768-24-000045 EDGAR
2024-05-09 0001802768-24-000021 EDGAR
2023-11-08 0001802768-23-000029 EDGAR
2023-08-08 0001802768-23-000023 EDGAR
2023-05-09 0001802768-23-000015 EDGAR
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/E Ratio30.0
P/B Ratio3.7
P/S Ratio10.6
EV/EBITDA23.2
TTM Revenue$2.4B
TTM Net Income$0.8B
TTM EPS$1.91
ROE12.0%
Dividend Yield2.85%
Debt/Equity1.30